Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

Dow Jones
2025/03/24
 

By Adria Calatayud and Helena Smolak

 

Bayer shares fell sharply after the company was ordered to pay $2.1 billion by a jury in a Georgia state court, the latest legal defeat for the company in a case about its Roundup weedkiller.

The German agricultural and pharmaceutical group said the jury in a trial in the State Court of Cobb County, Georgia, on Friday reached a verdict in favor of the plaintiff. The verdict includes $2 billion in punitive damages and $65 million in compensatory damages, the company said.

Shares in Bayer were down 6.6% at 22.48 euros in European morning trade Monday, having fallen as much as 8.8% earlier. The stock is up about 16% since the start of the year, amid a rally in German shares.

"We disagree with the jury's verdict, as it conflicts with the overwhelming weight of scientific evidence and the consensus of regulatory bodies and their scientific assessments worldwide," Bayer said. "We believe that we have strong arguments on appeal to get this verdict overturned and the excessive and unconstitutional damage awards eliminated or reduced."

The company said damages in cases that reached final judgments were reduced by 90% overall compared with the original jury awards.

The decision marks the latest legal setback for a company that has been fighting for years lawsuits stemming from its $63 billion acquisition of U.S. agrochemical firm Monsanto, which developed Roundup, closed in 2018. Critics have argued that glyphosate, the active ingredient found in Roundup, causes cancer though Bayer has long maintained that glyphosate is safe to use.

Bayer said it is currently evaluating the cases that would present the best opportunity to file a petition for review by the U.S. Supreme Court.

The company has so far paid around $10 billion to settle disputed claims, a spokesman said. Around 67,000 cases were still pending at the end of January and the company set aside $5.9 billion to cover glyphosate litigations, according to its annual report.

Bayer's chief executive, Bill Anderson, previously said that significantly containing litigation by the end of 2026 was one of his priorities.

 

Write to Adria Calatayud at adria.calatayud@wsj.com and to Helena Smolak

 

(END) Dow Jones Newswires

March 24, 2025 05:22 ET (09:22 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10